Skip to main content
PFE
NYSE Life Sciences

Pfizer's Berobenatide Shows Nearly 16% Weight Loss in Phase 2b, Monthly Dosing Possible

Tom Rudovsky · Reported by Reuters
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$25.951
Mkt Cap
$148.414B
52W Low
$23.08
52W High
$28.745
52W Position info
12% above low
Off High info
9.7% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

PFE is trading near its 52-week low of $23.08 (12% above the low).

Summary

Pfizer announced strong Phase 2b clinical trial results for its obesity drug candidate, Berobenatide (Vesper-1), demonstrating nearly 16% weight loss at 32 weeks with a 2.4 mg weekly dose. The data also highlighted robust efficacy and favorable tolerability, supporting the potential for a convenient monthly dosing regimen. This news follows Pfizer's strategic acquisition of Metsera's obesity assets in April, underscoring the company's aggressive entry into the highly lucrative weight loss market. A drug with this level of efficacy and a potential monthly dosing advantage could be a significant differentiator and a major revenue driver for Pfizer. The company plans to initiate 10 Phase 3 Berobenatide studies in 2026 as part of its broader commitment to over 20 obesity trials.

At the time of this announcement, PFE was trading at $25.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $148.4B. The 52-week trading range was $23.08 to $28.75. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.


Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 13, 2026, 3:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.85
Real-time Price: $28.93 info
Change: +$0.075 (+0.26%) info
Market Cap: $164.669B info
PFE
Nov 11, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.45
Real-time Price: $28.93 info
Change: -$0.5225 (-2%) info
Market Cap: $164.669B info
PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $28.93 info
Change: -$1.73 (-6%) info
Market Cap: $164.669B info
PFE
Nov 03, 2026, 8:07 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $30.62
Real-time Price: $28.93 info
Change: -$1.70 (-6%) info
Market Cap: $164.669B info
PFE
Nov 03, 2026, 6:55 AM EST
Source: Reuters
Importance Score:
8
Price at Filing: $30.73
Real-time Price: $28.93 info
Change: -$1.80 (-6%) info
Market Cap: $164.669B info